No potential conflicts of interest relevant to this article were reported. During this work, MHR received honoraria from DAEHWA Pharmaceuticals, Bristol Myers Squibb, Lilly, Ono Pharmaceuticals, MSD, Taiho Pharmaceuticals, Novartis, Daiichi Sankyo, and AstraZeneca; and served as a consultant for DAEHWA Pharmaceuticals, Bristol Myers Squibb, Lilly and Ono Pharmaceuticals. HDK received honoraria from AstraZeneca, Bristol Myers Squibb, Ono Pharmaceuticals, Boryung Pharmaceuticals, MSD, Daiichi Sankyo, and Boostimmune; received research grants from AstraZeneca and Roche/Genentech; and served as a consultant for Mustbio.

This report was approved by the Institutional Review Board of the Asan Medical Center (AMC 2024–0228).